What happened
ST Pharm filed provisional (unaudited) consolidated results for Q4 2025: revenue of US$88.2M (+11.4% year on year), operating profit of US$18.1M (+15.9% year on year) and net income of US$21.2M (+148.9% year on year).
These are preliminary figures the company disclosed ahead of its audited report; the final numbers can differ.
| Revenue | US$88.2M |
|---|---|
| Revenue vs a year earlier | +11.4% |
| Operating profit | US$18.1M |
| Net income | US$21.2M |
| Period | Q4 2025 (consolidated) |
| Filed | 2026-02-09, Operating results (consolidated) (preliminary) (fair disclosure) |
| Source | DART rcept 20260209900586 → open original filing |
Source: DART. Information only, not investment advice.